Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDS-related non-Hodgkin lymphoma and Multicentric Castleman's disease.
Moores Cancer Center, University of California, San Diego, USA.
Erin
E
Reid
Ajay
A
Nooka
Jawaunna
J
Blackmon
Mary Jo
MJ
Lechowicz
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005871:Castleman Disease / Q000188:drug therapy*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab